Abstract
Although the causes of Parkinson's disease are not yet fully understood, it has been established that some defect in the basal ganglia of the brain is heavily responsible. It has also been observed that the concentration of the transmitter substance dopamine is indeed very low in such cases. Therefore a symptomatic therapy in which a precursor of dopamine (levodopa) is administered orally has become a fairly standard treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
